Monitoring of HBsAg and Risk of HBV Infection in Patients with Multiple Myeloma

Abstract

To explore the incidence of HBsAg and the risk of HBV infection in patients with multiple myeloma (MM). A total of 114 newly diagnosed MM patients admitted in our hospital from May 2014 to July 2016 were enrolled in MM group, 110 healthy persons were enrolled in control group. The HBsAg positive rate and HBV infection rate were compared between 2 groups; the HBV infection rate of MM patients was compared before and after chemotherapy. According to detected results, all patients were divided into HBsAg+ group and HBsAg- group, and the lever damage in 2 groups was compared before and after treatment. For HBsAg+ and HBV-DNA+ patients, the preventive antiviral treatment was performed, while for other patients the preventive antiviral treatment was not performed, then the HBV reactivation was tested in each group. The incidence of HBsAg+ in MM patients seem a litter higher than that in control group without statistical significance (P>0.05); the incidence and severity of HBsAg+ group were higher than those of control group before treatment, moreover the difference between 2 groups was more significant after treatment (P< 0.05). The HBsAg reactivation was not found in 4 pases with HBsAg+ who received the proventive antiviral treatment, while the HBsAg reactivation was observed in 2 cases out of 6 cases without proventive antiviral treatment; the HBsAg reactivation happened only in 1 case of HBsAg- group after treatment. The HBV infection rate in MM patients after chemotherapy was significantly enhenced as compared with infection rate before chemotherapy(P< 0.05). The HBV infection rate in MM patients is higher than that in normal persons, moreover tha HBV-reactivation may happen in patients with ocult HBV infection in process of treatment; the HBV infection correlates with MM to a certain degree. The monitoring HBsAg for MM patients contributes to evaluation of liver danage.